IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.015
+0.010 (1.00%)
At close: Jun 6, 2025, 4:00 PM
1.030
+0.015 (1.48%)
After-hours: Jun 6, 2025, 6:41 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $725.00K in the quarter ending March 31, 2025, a decrease of -2.42%. This brings the company's revenue in the last twelve months to $3.27M, up 0.34% year-over-year. In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth.
Revenue (ttm)
$3.27M
Revenue Growth
+0.34%
P/S Ratio
16.62
Revenue / Employee
$49,591
Employees
66
Market Cap
59.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.21M | 132.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ICCM News
- 10 days ago - IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - IceCure Medical Reports First Quarter 2025 Financial Results - PRNewsWire
- 17 days ago - IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025 - PRNewsWire
- 4 weeks ago - IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation - PRNewsWire
- 5 weeks ago - IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer - PRNewsWire
- 5 weeks ago - IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium - PRNewsWire
- 6 weeks ago - IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - PRNewsWire
- 2 months ago - IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript - Seeking Alpha